{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:03:23Z","timestamp":1759104203393,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jneuroim.2017.12.015","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T13:13:53Z","timestamp":1513775633000},"page":"50-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["What is the role of interleukin 33 and ST2 receptor in myasthenia gravis?"],"prefix":"10.1016","volume":"315","author":[{"given":"Izabela Monika","family":"Rozmilowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika Helena","family":"Adamczyk-Sowa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2017.12.015_bb0005","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/eji.200838575","article-title":"The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-g production","volume":"39","author":"Bourgeois","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0010","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.4049\/jimmunol.179.4.2551","article-title":"IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex","volume":"179","author":"Chackerian","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0015","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/mp.2009.10","article-title":"Transcriptomic andgenetic studies identify IL-33 as a candidate gene for Alzheimer's disease","volume":"14","author":"Chapuis","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0020","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood-2009-02-203372","article-title":"Interleukin-33 induces angiogenesis and vascular permability through ST2\/TRAF6-mediated endothelial nitric oxide production","volume":"114","author":"Choi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40478-016-0344-1","article-title":"Role of IL-33 and ST2 signalling pathway in multiple sclerosis: expression by oligodendrocytes and inhibition of myelination in central nervous system","volume":"4","author":"Debbie","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0030","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/14737175.9.3.351","article-title":"Autoimmune myasthenia gravis","volume":"9","author":"Gilhus","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0040","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12264-011-1025-5","article-title":"Research progress on interleukin-33 and its roles in the central nervous system","volume":"27","author":"Han","year":"2011","journal-title":"Neurosci. Bull."},{"issue":"36","key":"10.1016\/j.jneuroim.2017.12.015_bb0045","doi-asserted-by":"crossref","first-page":"26369","DOI":"10.1074\/jbc.M704916200","article-title":"Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation","volume":"282","author":"Hayakawa","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.jneuroim.2017.12.015_bb0050","doi-asserted-by":"crossref","first-page":"e80695","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0055","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.4049\/jimmunol.0901575","article-title":"IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation","volume":"183","author":"Kurowska-Stolarska","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0060","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.smim.2013.10.006","article-title":"Special aspects of interleukin-33 and the IL-33 receptor complex","volume":"25","author":"Martin","year":"2013","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.jneuroim.2017.12.015_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-014-0179-6","article-title":"IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis","volume":"3","author":"Maurer","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"issue":"5","key":"10.1016\/j.jneuroim.2017.12.015_bb0070","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"issue":"22","key":"10.1016\/j.jneuroim.2017.12.015_bb0075","first-page":"1","article-title":"Role of IL-33 in inflammation and disease","volume":"8","author":"Miller","year":"2011","journal-title":"J. Inflamm."},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20071868","article-title":"IL-33 reduces the development of atherosclerosis","volume":"205","author":"Miller","year":"2008","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.jneuroim.2017.12.015_bb0085","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.pediatrneurol.2014.12.006","article-title":"Increase in circulating B cell-activating factor in childhood-onset ocular myasthenia gravis","volume":"52","author":"Motobayashi","year":"2015","journal-title":"Pediatr. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2017.12.015_bb0090","first-page":"e826","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0095","doi-asserted-by":"crossref","first-page":"18581","DOI":"10.1073\/pnas.1003059107","article-title":"IL-33 is a crucial amplifier of innate rather than acquired immunity","volume":"107","author":"Oboki","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0100","doi-asserted-by":"crossref","DOI":"10.14336\/AD.2016.0207","article-title":"Serum IL-33 is a novel diagnostic and prognostic biomarker in acute ischemic stroke","author":"Qian","year":"2016","journal-title":"Aging Dis."},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0105","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaci.2009.02.026","article-title":"IL-33-activated dendritic cells induce an atypical TH2-type response","volume":"123","author":"Rank","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.jneuroim.2017.12.015_bb0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.clim.2009.03.523","article-title":"IL-4 receptor as a bridge between the immune system and muscle in experimental myasthenia gravis I: up-regulation of muscle IL-15 by IL-4","volume":"132","author":"Shandley","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0120","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/intimm\/dxn060","article-title":"IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells","volume":"20","author":"Smithgall","year":"2008","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jneuroim.2017.12.015_bb0125","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1006\/bbrc.2001.5306","article-title":"Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V","volume":"285","author":"Tago","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.jneuroim.2017.12.015_bb0130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cei.12272","article-title":"Serum cytokine and chemokine profiles in patients with myasthenia gravis","volume":"176","author":"Uzawa","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.jneuroim.2017.12.015_bb0135","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.4049\/jimmunol.175.3.2018","article-title":"IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and antiacetylcholine receptor IgG1","volume":"175","author":"Yang","year":"2005","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.jneuroim.2017.12.015_bb0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2010.07.003","article-title":"Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer's disease","volume":"33","author":"Yu","year":"2012","journal-title":"Neurobiol. Aging"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572817301601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572817301601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:30:10Z","timestamp":1759048210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572817301601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":28,"alternative-id":["S0165572817301601"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2017.12.015","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What is the role of interleukin 33 and ST2 receptor in myasthenia gravis?","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2017.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}